334 related articles for article (PubMed ID: 16540658)
41. Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice.
DeMiguel F; Lee SO; Lou W; Xiao X; Pflug BR; Nelson JB; Gao AC
Prostate; 2002 Jul; 52(2):123-9. PubMed ID: 12111703
[TBL] [Abstract][Full Text] [Related]
42. Characterization of a transplantable hormone-responsive human prostatic cancer xenograft TEN12 and its androgen-resistant sublines.
Harper ME; Goddard L; Smith C; Nicholson RI
Prostate; 2004 Jan; 58(1):13-22. PubMed ID: 14673948
[TBL] [Abstract][Full Text] [Related]
43. Conditional Akt activation promotes androgen-independent progression of prostate cancer.
Li B; Sun A; Youn H; Hong Y; Terranova PF; Thrasher JB; Xu P; Spencer D
Carcinogenesis; 2007 Mar; 28(3):572-83. PubMed ID: 17032658
[TBL] [Abstract][Full Text] [Related]
44. Androgen axis in prostate cancer.
Culig Z; Bartsch G
J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
[TBL] [Abstract][Full Text] [Related]
45. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
Locke JA; Guns ES; Lubik AA; Adomat HH; Hendy SC; Wood CA; Ettinger SL; Gleave ME; Nelson CC
Cancer Res; 2008 Aug; 68(15):6407-15. PubMed ID: 18676866
[TBL] [Abstract][Full Text] [Related]
46. [Effects of anti-gene and antisense therapeutics on human prostate cancer xenograft in nude mice].
Zhang Y; Ma Y; Lu HP; Zhou XF; Xie Y; Gao JH; Liang CS
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(29):2073-6. PubMed ID: 19080439
[TBL] [Abstract][Full Text] [Related]
47. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells.
Lee SO; Pinder E; Chun JY; Lou W; Sun M; Gao AC
Prostate; 2008 Jan; 68(1):85-91. PubMed ID: 18008330
[TBL] [Abstract][Full Text] [Related]
48. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
49. Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens.
Thompson VC; Morris TG; Cochrane DR; Cavanagh J; Wafa LA; Hamilton T; Wang S; Fazli L; Gleave ME; Nelson CC
Prostate; 2006 Dec; 66(16):1698-709. PubMed ID: 16998820
[TBL] [Abstract][Full Text] [Related]
50. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
[TBL] [Abstract][Full Text] [Related]
51. Evolution of the androgen receptor pathway during progression of prostate cancer.
Hendriksen PJ; Dits NF; Kokame K; Veldhoven A; van Weerden WM; Bangma CH; Trapman J; Jenster G
Cancer Res; 2006 May; 66(10):5012-20. PubMed ID: 16707422
[TBL] [Abstract][Full Text] [Related]
52. Androgen receptor decoy molecules block the growth of prostate cancer.
Quayle SN; Mawji NR; Wang J; Sadar MD
Proc Natl Acad Sci U S A; 2007 Jan; 104(4):1331-6. PubMed ID: 17227854
[TBL] [Abstract][Full Text] [Related]
53. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
Seaton A; Scullin P; Maxwell PJ; Wilson C; Pettigrew J; Gallagher R; O'Sullivan JM; Johnston PG; Waugh DJ
Carcinogenesis; 2008 Jun; 29(6):1148-56. PubMed ID: 18487223
[TBL] [Abstract][Full Text] [Related]
54. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.
Snoek R; Cheng H; Margiotti K; Wafa LA; Wong CA; Wong EC; Fazli L; Nelson CC; Gleave ME; Rennie PS
Clin Cancer Res; 2009 Jan; 15(1):39-47. PubMed ID: 19118031
[TBL] [Abstract][Full Text] [Related]
55. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors.
Wu JD; Odman A; Higgins LM; Haugk K; Vessella R; Ludwig DL; Plymate SR
Clin Cancer Res; 2005 Apr; 11(8):3065-74. PubMed ID: 15837762
[TBL] [Abstract][Full Text] [Related]
56. Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways.
Yang Y; Ikezoe T; Takeuchi T; Adachi Y; Ohtsuki Y; Koeffler HP; Taguchi H
Oncol Rep; 2006 Jun; 15(6):1581-90. PubMed ID: 16685399
[TBL] [Abstract][Full Text] [Related]
57. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.
Agus DB; Scher HI; Higgins B; Fox WD; Heller G; Fazzari M; Cordon-Cardo C; Golde DW
Cancer Res; 1999 Oct; 59(19):4761-4. PubMed ID: 10519379
[TBL] [Abstract][Full Text] [Related]
58. Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells.
Deeble PD; Cox ME; Frierson HF; Sikes RA; Palmer JB; Davidson RJ; Casarez EV; Amorino GP; Parsons SJ
Cancer Res; 2007 Apr; 67(8):3663-72. PubMed ID: 17440078
[TBL] [Abstract][Full Text] [Related]
59. Androgen deprivation increases p300 expression in prostate cancer cells.
Heemers HV; Sebo TJ; Debes JD; Regan KM; Raclaw KA; Murphy LM; Hobisch A; Culig Z; Tindall DJ
Cancer Res; 2007 Apr; 67(7):3422-30. PubMed ID: 17409453
[TBL] [Abstract][Full Text] [Related]
60. MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2.
Ma S; Chan YP; Kwan PS; Lee TK; Yan M; Tang KH; Ling MT; Vielkind JR; Guan XY; Chan KW
Cancer Res; 2011 Jan; 71(2):583-92. PubMed ID: 21224345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]